Taltz FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 7, 2020.
FDA Approved: Yes (First approved March 22, 2016)
Brand name: Taltz
Generic name: ixekizumab
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis
Taltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of:
- patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- adults with active psoriatic arthritis.
- adults with active ankylosing spondylitis.
- adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
Development Timeline for Taltz
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.